Molecular diagnosis of COVID-19 â present experiences

Authors

  • Katarzyna Pancer Department of Virology, National Institute of Public Health-National Institute of Hygiene, Chocimska 24, 00-791 Warsaw, Poland
  • Magdalena Nowakowska Department of Bacteriology and Biocontamination Control, National Institute of Public Health-National Institute of Hygiene, Chocimska 24, 00-791 Warsaw, Poland
  • Agnieszka Kołakowska-Kulesza Department of Virology, National Institute of Public Health-National Institute of Hygiene, Chocimska 24, 00-791 Warsaw, Poland
  • Katarzyna Zacharczuk Department of Bacteriology and Biocontamination Control, National Institute of Public Health-National Institute of Hygiene, Chocimska 24, 00-791 Warsaw, Poland
  • Aleksandra A. Zasada Department of Sera and Vaccines Evaluation, National Institute of Public Health-National Institute of Hygiene, Chocimska 24, 00-791 Warsaw, Poland
  • Karol Szymański Department of Influenza Research, National Influenza Center, National Institute of Public Health-National Institute of Hygiene, Chocimska 24, 00-791 Warsaw, Poland
  • Karol Wdowiak Department of Sera and Vaccines Evaluation, National Institute of Public Health-National Institute of Hygiene, Chocimska 24, 00-791 Warsaw, Poland
  • Ewelina Hallmann Department of Influenza Research, National Influenza Center, National Institute of Public Health-National Institute of Hygiene, Chocimska 24, 00-791 Warsaw, Poland
  • Natalia Wolaniuk Department of Bacteriology and Biocontamination Control, National Institute of Public Health-National Institute of Hygiene, Chocimska 24, 00-791 Warsaw, Poland
  • Tomasz Wołkowicz Department of Bacteriology and Biocontamination Control, National Institute of Public Health-National Institute of Hygiene, Chocimska 24, 00-791 Warsaw, Poland
  • Adam Słoński Department of Parasitology and Vector-borne Diseases, National Institute of Public Health-National Institute of Hygiene, Chocimska 24, 00-791 Warsaw, Poland
  • Kamila Formińska Department of Sera and Vaccines Evaluation, National Institute of Public Health-National Institute of Hygiene, Chocimska 24, 00-791 Warsaw, Poland
  • Aleksandra Sadłocha Department of Bacteriology and Biocontamination Control, National Institute of Public Health-National Institute of Hygiene, Chocimska 24, 00-791 Warsaw, Poland
  • Ewa Mosiej Department of Sera and Vaccines Evaluation, National Institute of Public Health-National Institute of Hygiene, Chocimska 24, 00-791 Warsaw, Poland
  • Beata Gad Department of Virology, National Institute of Public Health-National Institute of Hygiene, Chocimska 24, 00-791 Warsaw, Poland
  • Arleta Krzysztoszek National Institute of Public Health - National Institute of Hygiene
  • Agnieszka Trzcińska Department of Virology, National Institute of Public Health-National Institute of Hygiene, Chocimska 24, 00-791 Warsaw, Poland

DOI:

https://doi.org/10.18388/pb.2020_363

Abstract

Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), a new highly emerging and pathogenic for human RNA virus, is responsible for the present COVID-19 pandemic. Molecular diagnostic methods, including real-time reverse transcription-PCR (RT-PCR) assay are the recommended methods for the identification and laboratory confirmation of COVID-19 cases. RT-PCR allows for detection the RNA of the virus in clinical specimens from patients suspected of COVID-19 with high specificity and sensitivity. Testing is still crucial for rapid detection of infected persons, implementation of appropriate measures to suppress further virus transmission and mitigate its impact. In response to demand of a molecular diagnostic test for SARS-CoV-2, within a first few months ongoing pandemic many commercial kits has become available on the market. However, these tests have varied in number and type of molecular targets, time of reaction as well as quality. In this study we compared different commercial tests for the detection of SARS-CoV-2 in clinical samples sending to Laboratory of Department of Virology, NIPH-NIH.

Downloads

Download data is not yet available.

Downloads

Published

2021-01-05

Issue

Vol. 66 No. 4 (2020): Special Issue "Viral Threats of the 21st Century"

Section

Articles

License

Copyright (c) 2021 Advances in Biochemistry

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All journal contents are distributed under the Creative Commons Attribution-ShareAlike 4.0 International (CC BY-SA 4.0) license. Everybody may use the content following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made, ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. There are no additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Copyright for all published papers © stays with the authors.

Copyright for the journal: © Polish Biochemical Society.